This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ACST Overzicht aandelen
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Acasti Pharma Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CA$0.58 |
| 52 Week Hoogtepunt | CA$1.66 |
| 52 Week Laag | CA$0.47 |
| Bèta | 1.22 |
| 11 maand verandering | -27.50% |
| 3 maanden verandering | -17.14% |
| 1 Jaar Verandering | -62.82% |
| 33 jaar verandering | -83.89% |
| 5 jaar verandering | -94.86% |
| Verandering sinds IPO | -98.87% |
Recent nieuws en updates
Rendement voor aandeelhouders
| ACST | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | -6.5% | 7.3% | -0.9% |
| 1Y | -62.8% | 40.8% | 27.4% |
Rendement versus industrie: ACST exceeded the Canadian Pharmaceuticals industry which returned -65.4% over the past year.
Rendement versus markt: ACST underperformed the Canadian Market which returned -11.9% over the past year.
Prijsvolatiliteit
| ACST volatility | |
|---|---|
| ACST Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 3.0% |
Stabiele aandelenkoers: ACST's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: ACST's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Jan D'Alvise | www.acastipharma.com |
Acasti Pharma Inc. Samenvatting
| ACST fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CA$19.23m |
| Inkomsten(TTM) | -CA$23.45m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-1.1x
Koers/WinstverhoudingIs ACST overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ACST resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$17.25m |
| Inkomsten | -US$17.25m |
Laatst gerapporteerde inkomsten
Dec 31, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.39 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ACST op de lange termijn?
Bekijk historische prestaties en vergelijking